CV Sciences (CVSI) EBT Growth (1y) (2012 - 2026)
CV Sciences (CVSI) EBT Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -324.14% |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | -1.93% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | -8.74% |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 70.52% |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 1.69% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 124.00% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn | -195.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -195.02% |
| Mar 31, 2026 | -530.39% |
| Dec 31, 2025 | 134.03% |
| Sep 30, 2025 | 16.23% |
| Jun 30, 2025 | 55.31% |
| Mar 31, 2025 | 83.60% |
| Dec 31, 2024 | 45.44% |
| Sep 30, 2024 | -2.01% |
| Jun 30, 2024 | 54.55% |
| Mar 31, 2024 | -110.90% |
| Dec 31, 2023 | 62.83% |
| Sep 30, 2023 | 56.64% |
| Jun 30, 2023 | 51.53% |
| Mar 31, 2023 | 369.79% |
| Dec 31, 2022 | 73.62% |
| Sep 30, 2022 | -2,477.50% |
| Jun 30, 2022 | 24.67% |
| Mar 31, 2022 | 32.36% |
| Dec 31, 2021 | 5.47% |
| Sep 30, 2021 | 98.73% |